Drug · DIN 02425491
INVOKANA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 28, 2014; first marketed May 28, 2014.
- Drug Identification Number (DIN)
- 02425491
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Canagliflozin A10BK02
- Class
- Human
- Record last updated
- June 16, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CANAGLIFLOZIN | 300 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 10, 2016: NOC 18355Supplement to a New Drug Submission (SNDS) · Update to the product monograph in response to an advisement letter issued april 15, 2016
- May 23, 2014: NOC 15626New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “invokana”. A notice may cover another product or only some lots: read it to see what it covers.
- INVOKANA® (canagliflozin) and INVOKAMET® (canagliflozin and metformin) - Risk of Lower Limb AmputationSeptember 6, 2017 · Drugs
- SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic KetoacidosisMay 16, 2016 · Drugs · Product safety
- Forxiga, Invokana: Health Canada begins safety review of diabetes drugs known as SGLT2 inhibitors and risk of ketoacidosisJune 22, 2015 · Drugs · Product safety
Other DINs named INVOKANA
- DIN 02425483 · Marketed